Plasmodium Falciparum Malaria (Drug Resistant) Recruiting Phase 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0114433 (Plasmodium Falciparum Malaria (Drug Resistant))Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03697668Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant ParasitesTreatment